Related Experiment Videos
Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach
E Hauge1, L Mosekilde, F Melsen
1Institute of Pathology, Aarhus University Hospital, Denmark. ellen.hauge@dadlnet.dk
Bone
|October 8, 1999
Summary
Missing data in bone histomorphometry can cause selection bias, overestimating bone turnover. Recoding missing values is crucial for accurate osteoporosis assessment, especially in older, osteopenic women.
Area of Science:
- Bone Biology
- Histomorphometry
- Osteoporosis Research
Background:
- Bone histomorphometry relies on tetracycline double labeling for turnover indices.
- Missing readings in double labels can lead to information loss and selection bias.
- Exclusion of biopsies with missing data may skew results towards high-turnover patients.
Purpose of the Study:
- To analyze the impact of excluding iliac crest bone biopsies with missing readings in women with spinal crush fracture osteoporosis.
- To evaluate the utility of mineral apposition rate (MAR) lower limits for recoding missing data.
- To investigate potential selection bias in bone histomorphometric trials.
Main Methods:
- Analysis of iliac crest bone biopsies from 158 women with spinal crush fracture osteoporosis.
- Examination of two lower limits for MAR to recode missing interlabel width (Ir.L.Wi) values.
- Comparison of histomorphometric indices with and without exclusion of cases with missing readings.
Main Results:
- Excluding biopsies with missing data increased mineralizing surface (MS/BS) by 60%.
- A recoding procedure using a minimal MAR of 0.1 microm/day (Ir.L.Wi = 1 microm) decreased average MAR by 4% and prolonged remodeling period by 19%.
- Biopsy exclusion was more prevalent in older and more osteopenic individuals, suggesting bias.
Conclusions:
- Ignoring missing double labels in bone histomorphometry introduces selection bias, favoring high-turnover patients.
- Recoding procedures are necessary to accurately represent low-turnover patients.
- Exclusion of older, osteopenic patients poses a risk of bias in osteoporosis trials.